Quantitation of analytes in whole blood
AssigneeSepsis, Inc.
InventorsAlexander D. Romaschin, Paul M. Walker
Life of this patent
Estimating the term…
Loading patent…
AssigneeSepsis, Inc.
InventorsAlexander D. Romaschin, Paul M. Walker
Estimating the term…
The invention relates to a method for quantitating the level of a preselected analyte in a sample of blood of a human or animal patient by incubating the test sample with an antibody specific to the analyte to form an immunocomplex, which then interacts with the white blood cell fractions and result in the production of oxidants. Oxidants are detected using chemiluminescent reagents. In addition, the white blood cell oxidant response may be enhanced by the inclusion of certain agents such as opsonized zymosan. As part of the assay, separate blood samples are also maximally stimulated with a maximal stimulatory amount of exogenously-added antigen, and corresponding antibody, to form immunocomplexes, to provide a response factor used in the quantitation of analyte. This quantitative method may be used to determine levels of analytes in a sample of a patient's blood including endotoxin and other analytes related to sepsis, in order to select the proper therapeutic course, or may be used to measure other analytes such as inflammatory mediators, hormones, acute phase proteins, toxins, drugs of abuse, markers of cardiac muscle damage, therapeutic drugs, cytokines, and chemokines.
A method for quantitating the level of a preselected analyte present in a sample of blood of a human or animal patient, said sample comprising plasma and white blood cells, said method sequentially comprising:
A diagnostic kit for quantitating the level of a preselected analyte present within sample of blood of a human or animal patient, said sample comprising plasma and white blood cells, said diagnostic kit comprising:
Dependencies are inferred from the claim text.